Full article view2017-09-21T08:01:31+00:00

Precision’s Edgar, Grosvenor, and Rademacher Guest Authors in Biosimilar Development


In Part 1 of a two-part series, Todd Edgar, Alex Grosvenor, and Kellie Rademacher discuss EU biosimilar policies and their impact on the US approach, with a focus on payer coverage. Check back soon for Part 2, highlighting the effects of the NOR-SWITCH trial results and how the EU’s view of biosimilars as therapeutic alternatives, rather than generics, has influenced US policy.

To read the article please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.